Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.52

+0.4%

Nov 28 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: gcrispin	5/25/2005 10:00:50 AM
	Read Replies (1) of 52153

From the LA Times: Steven Schwartz of UCLA's Jules Stein Eye Institute said Lucentis looked promising but it was not fair to compare it with Macugen based on the data released Monday. Schwartz said Macugen was tested in patients with aggressive age-related macular degeneration but Lucentis was not, and that could at least partially explain the different results. Genentech said patients with the aggressive form of age-related macular degeneration were participating in a separate clinical trial scheduled to end in the fourth quarter of this year. That trial is a head-to-head study of Lucentis against Visudyne, a drug that is used with lasers to slow the disease.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next